| 1 |
Kaushal N, Baranwal M. Mutational analysis of catalytic site domain of CCHFV L RNA segment. J Mol Model 2023;29:88. [PMID: 36877258 DOI: 10.1007/s00894-023-05487-7] [Reference Citation Analysis]
|
| 2 |
Bodie NM, Hashimoto R, Connolly D, Chu J, Takayama K, Uhal BD. Design of a chimeric ACE-2/Fc-silent fusion protein with ultrahigh affinity and neutralizing capacity for SARS-CoV-2 variants. Antib Ther 2023;6:59-74. [PMID: 36741194 DOI: 10.1093/abt/tbad001] [Reference Citation Analysis]
|
| 3 |
Lin J, Anjum Huma F, Irfan A, Ali SS, Waheed Y, Mohammad A, Munir M, Khan A, Wei D. Structural plasticity of omicron BA.5 and BA.2.75 for enhanced ACE-dependent entry into cells. Journal of Biomolecular Structure and Dynamics 2022. [DOI: 10.1080/07391102.2022.2158944] [Reference Citation Analysis]
|
| 4 |
Takaoka Y, Sugano A, Morinaga Y, Ohta M, Miura K, Kataguchi H, Kumaoka M, Kimura S, Maniwa Y. Prediction of infectivity of SARS-CoV2: Mathematical model with analysis of docking simulation for spike proteins and angiotensin-converting enzyme 2. Microb Risk Anal 2022;22:100227. [PMID: 35756961 DOI: 10.1016/j.mran.2022.100227] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 5 |
Sharma P, Kumar M, Tripathi MK, Gupta D, Vishwakarma P, Das U, Kaur P. Genomic and structural mechanistic insight to reveal the differential infectivity of omicron and other variants of concern. Computers in Biology and Medicine 2022;150:106129. [DOI: 10.1016/j.compbiomed.2022.106129] [Reference Citation Analysis]
|
| 6 |
Saifi S, Ravi V, Sharma S, Swaminathan A, Chauhan NS, Pandey R. SARS-CoV-2 VOCs, Mutational diversity and clinical outcome: Are they modulating drug efficacy by altered binding strength? Genomics 2022;114:110466. [PMID: 36041637 DOI: 10.1016/j.ygeno.2022.110466] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 7 |
Bodie NM, Connolly D, Chu J, Uhal BD. DESIGN OF A CHIMERIC ACE-2/Fc-SILENT FUSION PROTEIN WITH ULTRAHIGH AFFINITY AND NEUTRALIZING CAPACITY FOR SARS-CoV-2 VARIANTS.. [DOI: 10.1101/2022.06.23.497326] [Reference Citation Analysis]
|
| 8 |
Takaoka Y, Sugano A, Morinaga Y, Ohta M, Miura K, Kataguchi H, Kumaoka M, Kimura S, Maniwa Y. Prediction of infectivity of SARS-CoV2: Mathematical model with analysis of docking simulation for spike proteins and angiotensin-converting enzyme 2.. [DOI: 10.1101/2022.03.30.486373] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
